Carnitine Palmitoyltransferase II Deficiency (CPT II) Followed By Rhabdomyolysis and Acute Kidney Injury
- PMID: 29731937
- PMCID: PMC5927500
- DOI: 10.3889/oamjms.2018.158
Carnitine Palmitoyltransferase II Deficiency (CPT II) Followed By Rhabdomyolysis and Acute Kidney Injury
Abstract
Background: Carnitine palmitoyltransferase II deficiency (CPT II) is an autosomal recessive disorder and the most common inherited disorder of mitochondrial long-chain fatty acid oxidation, characterised by attacks of myalgia and myoglobinuria. The most common "classic" myopathic form occurs in young adults and is characterised by recurrent episodes of rhabdomyolysis triggered by prolonged exercise, fasting or febrile illness.
Case presentation: We present a case of a 22-year-old Caucasian male admitted to our hospital with fever, dyspnea, fatigue, myalgia and dark urine (brown-coloured). The symptoms appeared after viral infection followed by fever. Acute kidney injury (AKI) developed as a complication, and there was a need for treatment with hemodialysis. At the clinical presentation, the patient had plasma creatine kinase (pCK) level of 130.383 U/L and plasma myoglobin level over 5000 µg/L. Genetic testing (molecular analysis) confirmed the diagnosis of inherited rhabdomyolysis, a metabolic disorder of carnitine palmitoyltransferase II deficiency. A previous episode with the same symptoms, the patient had four years ago but did not ask for medical treatment. The patient was discontinued from hemodialysis because of the resolution of acute kidney injury. The patient was discharged from the hospital in good condition, with a recommendation about his future lifestyle in order to prevent similar episodes.
Conclusion: Every patient presenting with myalgia, dark urine (brown-coloured), high level of pCK and development of AKI requiring hemodialysis, should be explored for inherited rhabdomyolysis induced by CPT II deficiency.
Keywords: Acute kidney injury; Carnitine palmitoyltransferase II deficiency; Creatine kinase; Hemodialysis; Metabolic disorder; Myoglobin; Rhabdomyolysis.
References
-
- Sigauke E, Rakheja D, Kitson K, Bennett MJ. Carnitine palmitoyltransferase II deficiency: A clinical, biochemical, and molecular review. Lab Invest. 2000;383:1543–1554. - PubMed
-
- Bonnefont JP, Demaugre F, Prip-Buus C, Saudubray JM, Brivet M, Abadi N, Laure Thuillier L. Carnitine Palmitoyltransferase Deficience. Mol Genet Metab. 1999;68(4):424–40. https://doi.org/10.1006/mgme.1999.2938. PMid:10607472. - PubMed
-
- Giannoglou GD, Chatzizisis YS, Misirli G. The syndrome of rhabdomyolysis: Pathophysiology and diagnosis. Eur J Intern Med.2007; 18:90. https://doi.org/10.1016/j.ejim.2006.09.020. PMid:17338959. - PubMed
-
- Vladutiu GD, Quackenbush EJ, Hainline BE, Albers S, Smail DS, Bennett MJ. Lethal neonatal and severe late infantile forms of carnitine palmitoyltransferase II deficiency associated with compound heterozygosity for different protein truncation mutations. J Pediatr. 2002;141:734–6. https://doi.org/10.1067/mpd.2002.128545. PMid:12410208. - PubMed
-
- Anichini A, Fanin M, Vianey-Saban C, Cassandrini D, Fiorillo C, Bruno C, Angelini C. Genotype-phenotype correlations in a large series of patients with muscle type CPT II deficiency. Neurol Res. 2011;33(1):24–32. https://doi.org/10.1179/016164110X12767786356390. PMid:20810031. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources